Effect of Lithium Therapy on Long COVID Symptoms

This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.

Documented or self-reported positive test for COVID-19 ≥4 weeks prior to enrollment.No fever for ≥4 weeks prior to enrollment.Reports fatigue and/or brain fog (i.e. concentration or memory impairment) for ≥4 weeks prior to enrollment on the PASC-Specific Symptom questionnaire beginning after infection with COVID-19.Fatigue Severity Scale (FSS) score ≥28 or Brain Fog Severity Scale (BFSS) score ≥28 at baseline.Beck Depression Inventory II score <24.No change in any psychoactive or steroid medications for ≥30 days.No plan to change any psychoactive, steroid or diuretic medication for ≥5 weeks and not planning on obtaining a COVID vaccine within the next 5 weeks.Not using any long COVID therapies felt to be worsening the patient's symptoms or starting a long COVID therapy within the next 5 weeks.No history of fibromyalgia, chronic fatigue syndrome or progressive cognitive disorder prior to COVID-19 infection.No active medical, psychiatric or social problems that would interfere with completing the study procedures in the opinion of the investigator.No use of tobacco or marijuana products for >6 months and no current alcohol abuse (≥4 drinks/day) or illicit drug use.Not receiving or applying for disability payments or workman's compensation for long COVID.Not pregnant or nursing or planning to get pregnant over the next two months.